SEC
TVTX icon

Seven Eight Capital’s Travere Therapeutics TVTX Stock Holding History

Seven Eight Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,766
Closed -$242K – 654
2023
Q1 		$242K Buy
+10,766
New +$229K 0.05% 368

Other funds holding TVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Seven Eight Capital's TVTX Position: Q2 2023 in Review

Seven Eight Capital sold out of Travere Therapeutics (TVTX) in Q2 2023, closing a stake of 10,766 shares — an estimated $242K sold.

Seven Eight Capital first reported a position in TVTX in Q1 2023 and held it in 1 quarter. The position peaked at $242K in Q1 2023. 169 funds tracked by Wall St. Rank hold TVTX as of Q2 2023.

  • Seven Eight Capital reported no remaining Travere Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Seven Eight Capital sold 10,766 Travere Therapeutics shares in Q2 2023, an estimated $242K.
  • Seven Eight Capital first reported a position in Travere Therapeutics in Q1 2023 and held it in 1 quarter.
  • Seven Eight Capital's Travere Therapeutics position peaked at $242K in Q1 2023.
  • 169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2023.

Based on Seven Eight Capital's 13F filing for Q2 2023, filed 14 Aug 2023.